IPHA 外汇新闻

Innate Pharma SA (IPHA) announced Thursday that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the lacutamab IND. This has led to a pause in new patient enrollment to the Company's ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL).